CVC Capital Partners ("CVC") today announced the closing of CVC Fund VI's acquisition of the international women's health assets which CVC Fund VI agreed to acquire from Teva Pharmaceutical Industries Ltd in Q3 2017.

The new company, called Theramex, is a global specialty pharmaceutical company dedicated to women and their health. Headquartered in London, UK, the company will market a broad range of innovative, branded and branded generic products across 50 countries around the world. The portfolio, which is dedicated to women's health, focuses on contraception, fertility, menopause and osteoporosis and includes key brands such as Ovaleap®, Zoely®, Seasonique®, Actonel®, Estreva® and Lutenyl®. The Theramex brand enjoys a long heritage in women's health across a number of countries in Europe, and has strong resonance among patients, practitioners and current employees.

Anish Mehta, CEO of Theramex, said: "I am delighted and honoured to launch the new Theramex, a specialty pharmaceutical company dedicated to women and their health. Our commitment is to provide innovative, effective and safe solutions that care for and support women as they advance through each stage of their lives. We look forward to building on our strong heritage and enhancing our differentiated product portfolio to advance women's health."

Cathrin Petty, Partner and Head of European Healthcare at CVC, added: "Women's health is a rapidly growing segment of the healthcare sector, and one which we at CVC are watching closely. I am very pleased to announce the closing of CVC Fund VI's investment in Theramex, and look forward to working with this highly talented team.  We intend to continue to grow the company through business development and further acquisitions."

In November 2017, CVC announced that Fred Hassan was appointed as chairman of Theramex. Mr Hassan was chairman of the board and CEO of Schering-Plough Corporation from 2003 to 2009. Before joining Schering-Plough, Mr Hassan also served as chairman and CEO of Pharmacia Corporation from its creation in 2000, and has held other senior positions with Wyeth and Sandoz Pharmaceuticals.

Rothschild & Co, Royal Bank of Canada, Jefferies LLC and Barclays acted as financial advisors, to CVC Capital Partners for the transaction. Latham Watkins and Jones Day acted as legal advisors to CVC Capital Partners.